PEGylated Compstatin Dosing for Acute Complement Inhibition
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
There is a need for compositions that can acutely inhibit complement activity, particularly in treating complement-mediated disorders.
Innovation Solution
Intravenous administration of PEGylated compstatin analogs, ranging from 100 mg to 2500 mg, with a PEG of about 40 kD, to inhibit complement activity for 2 to 336 hours, and optionally followed by subcutaneous administration, to treat complement-mediated disorders such as hemolytic anemia and PNH.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If PEGylated compstatin analog is administered to achieve acute complement inhibition, then complement activity is reduced effectively, but the duration of action is limited to several hours
Solution Approach 1:
The patent implements periodic dosing regimens where PEGylated compstatin analog is administered at intervals (e.g., every 2-7 days) to maintain therapeutic complement inhibition levels. This periodic administration ensures sustained efficacy while managing the limited duration of action of each individual dose.
Solution Approach 2:
The patent utilizes PEGylation with different molecular weights (e.g., 20 kD, 40 kD, 60 kD) to modify the pharmacokinetic parameters of compstatin analog. This chemical modification extends the half-life and duration of action while maintaining complement inhibition efficacy, directly addressing the limited duration problem.
2Reliability
If high dose PEGylated compstatin analog is administered to ensure adequate complement inhibition, then therapeutic effect is improved, but the complexity of dosing regimen increases
Solution Approach 1:
The patent establishes standardized dosing parameters including specific dose ranges (e.g., 100-2500 mg), fixed dosing intervals (every 2-7 days), and controlled infusion rates (e.g., 6.5-80 mg/min). These standardized parameters simplify the dosing regimen while ensuring adequate therapeutic effect through systematic parameter optimization.
3Speed
If rapid complement inhibition is achieved through intravenous administration, then acute hemolysis is treated effectively, but the ease of operation is reduced due to infusion requirements
Solution Approach 1:
The patent employs periodic intravenous infusions at scheduled intervals to achieve rapid complement inhibition when needed (e.g., during acute hemolysis episodes) while allowing for periods between treatments. This periodic approach balances the need for rapid action with the burden of frequent hospital visits.
Solution Approach 2:
The patent introduces PEGylation as an intermediary modification that enables the drug to achieve both rapid onset (through intravenous delivery) and extended duration of action. The PEG moiety acts as a mediator that prolongs circulation time, reducing the frequency of administrations and thereby improving ease of operation while maintaining rapid inhibition capability.
Data Source
AI summary
Complement is an arm of the innate immune system that plays an important role in defending the body against infectious agents. Although compositions that inhibit complement are known, there remains a need for compositions that can acutely inhibit complement. Methods and compositions comprising PEGylated compstatin analog for inhibiting complement are described.